{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:44Z","timestamp":1792785884055,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"19","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"MOST","doi-asserted-by":"publisher","award":["107-2314-B-075-062-MY3"],"award-info":[{"award-number":["107-2314-B-075-062-MY3"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V107B-001"],"award-info":[{"award-number":["V107B-001"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V107B-022"],"award-info":[{"award-number":["V107B-022"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V107C-200"],"award-info":[{"award-number":["V107C-200"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Health Insurance Research Database","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bureau of National Health Insurance"},{"DOI":"10.13039\/501100003921","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014477","name":"National Health Insurance","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014477","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The stroke risk of patients with atrial fibrillation (AF) is not static, since AF patients get older and accumulate more comorbidities after AF is diagnosed. Therefore, the stroke risk of AF patients given certain comorbidities in different age strata should ideally be analysed using an assessment which considers incident comorbidities and the actual age when ischaemic stroke occurred. The goal of the present study is to report the age treatment thresholds for the use of non-vitamin K antagonist oral anticoagulants (NOACs) for AF patients without or with only one comorbidity of the CHA2DS2-VASc score, based on an \u2018ideal method\u2019 of stroke risk assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The study cohort included 31\u00a0039 and 39\u00a0020 AF patients who did not have any or had only one risk factor comorbidity of the CHA2DS2-VASc score except for age and sex. The risks of ischaemic stroke in each age strata for each comorbidities were analysed in three ways, as follows: (i) the conventional way (based on baseline risk factors and age), (ii) dynamic method (patients were censored when new comorbidities occurred), and (iii) an ideal method (patients were censored when new comorbidities occurred and the stroke risk was related to the actual age when stroke happened). The tipping point for the use of NOACs was set at a stroke risk of 0.9%\/year. The overall risk of ischaemic stroke using the conventional way was overestimated compared to the dynamic or ideal assessment with the incidence rate ratio of 1.24 for patients with hypertension, 1.20 for heart failure, 1.37 for diabetes mellitus, and 1.38 for vascular diseases; all P-values &amp;lt;0.01. The risk of ischaemic stroke for each age strata was generally higher with the conventional or dynamic methods compared with the ideal assessment. With heart failure, the tipping point (age 35\u2009years) of NOACs was similar, irrespective of methods used for stroke risk assessment. According to the results of ideal assessment, the age thresholds for the use of NOACs for patients with hypertension, diabetes mellitus, and vascular diseases were 50\u2009years, 50\u2009years, and 55\u2009years, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ischaemic stroke risk in AF is heterogeneous, depending on different risk factors with age being as an important driver of stroke risk. Age thresholds for the use of NOACs were different for AF patients having different single risk factors beyond sex despite the same CHA2DS2-VASc score point (1 for males and 2 for females); that is, 35\u2009years for heart failure, 50\u2009years for hypertension or diabetes, and 55\u2009years for vascular diseases.<\/jats:p>\n                    <jats:p\/>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehy837","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T07:15:39Z","timestamp":1544512539000},"page":"1504-1514","source":"Crossref","is-referenced-by-count":68,"title":["Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities"],"prefix":"10.1093","volume":"40","author":[{"given":"Tze-Fan","family":"Chao","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, 6 West Derby Street, Liverpool, UK"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenn-Jiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Lin","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wei","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Chuan","family":"Tuan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Nan","family":"Liao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Po","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzeng-Ji","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ann","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"2022102609534471500_ehy837-B1","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2022102609534471500_ehy837-B2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102609534471500_ehy837-B3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","article-title":"2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"Chiang","year":"2017","journal-title":"J Arrhythm"},{"key":"2022102609534471500_ehy837-B4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102609534471500_ehy837-B5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1378\/chest.15-1622","article-title":"Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project","volume":"149","author":"Fauchier","year":"2016","journal-title":"Chest"},{"key":"2022102609534471500_ehy837-B6","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/STROKEAHA.116.013253","article-title":"Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?","volume":"47","author":"Fauchier","year":"2016","journal-title":"Stroke"},{"key":"2022102609534471500_ehy837-B7","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jacc.2015.01.044","article-title":"Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score","volume":"65","author":"Lip","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102609534471500_ehy837-B8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","article-title":"Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1","volume":"65","author":"Friberg","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102609534471500_ehy837-B9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/CIRCULATIONAHA.116.024057","article-title":"Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation","volume":"135","author":"Quinn","year":"2017","journal-title":"Circulation"},{"key":"2022102609534471500_ehy837-B10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2015.07.026","article-title":"Age threshold for increased stroke risk among patients with atrial fibrillation: a Nationwide Cohort Study from Taiwan","volume":"66","author":"Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102609534471500_ehy837-B11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022102609534471500_ehy837-B12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102609534471500_ehy837-B13","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jacc.2014.06.1203","article-title":"Using the CHA2DS2-VASc score for refining stroke risk stratification in \u2018low-risk\u2019 Asian patients with atrial fibrillation","volume":"64","author":"Chao","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102609534471500_ehy837-B14","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1161\/CIRCULATIONAHA.114.013709","article-title":"Rate-control treatment and mortality in atrial fibrillation","volume":"132","author":"Chao","year":"2015","journal-title":"Circulation"},{"key":"2022102609534471500_ehy837-B15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.115.019794","article-title":"Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage","volume":"133","author":"Chao","year":"2016","journal-title":"Circulation"},{"key":"2022102609534471500_ehy837-B16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.mayocp.2016.03.007","article-title":"Impact on outcomes of changing treatment guideline recommendations for stroke prevention in atrial fibrillation: a Nationwide Cohort Study","volume":"91","author":"Chao","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2022102609534471500_ehy837-B17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chest.2017.10.001","article-title":"Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF Cohort Study","volume":"153","author":"Chao","year":"2018","journal-title":"Chest"},{"key":"2022102609534471500_ehy837-B18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2013.11.036","article-title":"Continuation of statin therapy and a decreased risk of atrial fibrillation\/flutter in patients with and without chronic kidney disease","volume":"232","author":"Chang","year":"2014","journal-title":"Atherosclerosis"},{"key":"2022102609534471500_ehy837-B19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pds.2087","article-title":"Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan","volume":"20","author":"Cheng","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022102609534471500_ehy837-B20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","article-title":"Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database","volume":"114","author":"Hsieh","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"2022102609534471500_ehy837-B21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/jth.13690","article-title":"Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis","volume":"15","author":"van Doorn","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2022102609534471500_ehy837-B22","doi-asserted-by":"crossref","first-page":"e0151485.","DOI":"10.1371\/journal.pone.0151485","article-title":"Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc score of 1 May not need anticoagulants: a Nationwide Population-Based Study","volume":"11","author":"Chan","year":"2016","journal-title":"PLoS One"},{"key":"2022102609534471500_ehy837-B23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurjhf\/hfs005","article-title":"Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project","volume":"14","author":"Banerjee","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2022102609534471500_ehy837-B24","first-page":"157","article-title":"Accuracy of diabetes diagnosis in health insurance claims data in Taiwan","volume":"104","author":"Lin","year":"2005","journal-title":"J Formos Med Assoc"},{"key":"2022102609534471500_ehy837-B25","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.hrthm.2014.04.021","article-title":"Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong","volume":"11","author":"Siu","year":"2014","journal-title":"Heart Rhythm"},{"key":"2022102609534471500_ehy837-B26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH15-03-0210","article-title":"The risks of risk scores for stroke risk assessment in atrial fibrillation","volume":"113","author":"Nielsen","year":"2015","journal-title":"Thromb Haemost"},{"key":"2022102609534471500_ehy837-B27","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"2022102609534471500_ehy837-B28","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke"},{"key":"2022102609534471500_ehy837-B29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"168","author":"Goto","year":"2014","journal-title":"Am Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/19\/1504\/46641646\/eurheartj_40_19_1504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/19\/1504\/46641646\/eurheartj_40_19_1504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T06:01:33Z","timestamp":1666764093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/19\/1504\/5272355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":29,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,1,2]]},"published-print":{"date-parts":[[2019,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehy837","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5,14]]},"published":{"date-parts":[[2019,1,2]]}}}